| 330 1.01 (0.31%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 387.28 | 1-year : | 452.34 |
| Resists | First : | 331.57 | Second : | 387.28 |
| Pivot price | 328.14  |
|||
| Supports | First : | 298.04 |
Second : | 277.32 |
| MAs | MA(5) : | 329 |
MA(20) : | 326.47 |
| MA(100) : | 250.11 |
MA(250) : | 242.44 |
|
| MACD | MACD : | 10.5  |
Signal : | 12.8 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 89.6 |
| RSI | RSI(14): 76.8 |
|||
| 52-week | High : | 331.57 | Low : | 157 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SWAV ] has closed below upper band by 7.1%. Bollinger Bands are 87.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 330.78 - 332.11 | 332.11 - 333.48 |
| Low: | 325.13 - 326.53 | 326.53 - 327.98 |
| Close: | 327.71 - 330.13 | 330.13 - 332.63 |
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Fri, 26 Apr 2024
Shockwave Medical, Inc. (NASDAQ:SWAV) Shares Bought by Jennison Associates LLC - MarketBeat
Thu, 25 Apr 2024
Why the Market Dipped But Shockwave Medical (SWAV) Gained Today - Zacks Investment Research
Wed, 24 Apr 2024
Shockwave Medical (SWAV) Rose on an Acquisition News and Solid Financial Result - Yahoo Finance Australia
Wed, 24 Apr 2024
Shockwave Medical (SWAV) Rose on an Acquisition News and Solid Financial Result - Yahoo Finance
Fri, 19 Apr 2024
Shockwave Medical (SWAV) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Fri, 12 Apr 2024
Shockwave Medical (SWAV) Rose on Strong Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 95.3 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 1,700 (K) |
| EPS | 3.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.07 |
| Profit Margin | 20.1 % |
| Operating Margin | 21.9 % |
| Return on Assets (ttm) | 9.3 % |
| Return on Equity (ttm) | 24.9 % |
| Qtrly Rev. Growth | 40.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 19.46 |
| EBITDA (p.s.) | 4.7 |
| Qtrly Earnings Growth | -69 % |
| Operating Cash Flow | 196 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | 85.71 |
| PEG Ratio | 2.7 |
| Price to Book value | 18.25 |
| Price to Sales | 16.95 |
| Price to Cash Flow | 63.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|